source
- Supernus and Indivior merge to form CNS-focused company with 11 marketed drugs and $2.2B revenue targetSupernus Pharmaceuticals and Indivior Pharmaceuticals announced an all‑stock merger of equals, creating a central nervous system‑focused company that will combine their product lines and operations…
- Curium to acquire Lantheus in deal valued up to $8 billionCurium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…